semaglutide fda submission Clears For Cardiac Risk Reduction in Diabetic Patients FDA crackdown on off-brand Ozempic

C-peptide for Type 2 Diabetes: In contrast, Type 2 diabetes patients typically have normal or increased levels of C-peptide, which reflects insulin resistance rather than a lack of insulin production

Additionally, we emphasize the importance of patient education and support resources as vital components in navigating this complex condition

DXA data from the STEP-1 and SURMOUNT-1 trials show meaningful lean mass reduction during GLP-1-driven weight loss: approximately 9.7% of total lean tissue with semaglutide in STEP-1, and 10.9% with tirzepatide in SURMOUNT-1

Fibromyalgia Fibromyalgia is a condition where central pain sensitization, rather than peripheral inflammation, drives the symptom picture

A scoping review of Pacing for management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Lessons learned for the long COVID pandemic

Our findings offer valuable insights into the relative efficacy of these GLP-1 RAs in clinical practice